Shanghai Yizhong Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Shanghai Yizhong Pharmaceutical has a total shareholder equity of CN¥1.5B and total debt of CN¥31.0M, which brings its debt-to-equity ratio to 2.1%. Its total assets and total liabilities are CN¥1.5B and CN¥75.5M respectively. Shanghai Yizhong Pharmaceutical's EBIT is CN¥80.0M making its interest coverage ratio -2.5. It has cash and short-term investments of CN¥733.5M.
Key information
2.1%
Debt to equity ratio
CN¥31.02m
Debt
| Interest coverage ratio | -2.5x |
| Cash | CN¥733.50m |
| Equity | CN¥1.46b |
| Total liabilities | CN¥75.52m |
| Total assets | CN¥1.54b |
Recent financial health updates
Recent updates
Is Shanghai Yizhong Pharmaceutical (SHSE:688091) Using Too Much Debt?
Aug 20
What Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) P/E Is Not Telling You
Jul 24Concerns Surrounding Shanghai Yizhong Pharmaceutical's (SHSE:688091) Performance
Apr 15Getting In Cheap On Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Is Unlikely
Mar 29Financial Position Analysis
Short Term Liabilities: 688091's short term assets (CN¥912.5M) exceed its short term liabilities (CN¥71.3M).
Long Term Liabilities: 688091's short term assets (CN¥912.5M) exceed its long term liabilities (CN¥4.2M).
Debt to Equity History and Analysis
Debt Level: 688091 has more cash than its total debt.
Reducing Debt: 688091's debt to equity ratio has increased from 0% to 2.1% over the past 5 years.
Debt Coverage: 688091's debt is well covered by operating cash flow (114.4%).
Interest Coverage: 688091 earns more interest than it pays, so coverage of interest payments is not a concern.